↓ Skip to main content

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Overview of attention for article published in Cardiovascular Diabetology, May 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#49 of 794)
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

26 tweeters


36 Dimensions

Readers on

104 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Published in
Cardiovascular Diabetology, May 2017
DOI 10.1186/s12933-017-0547-1
Pubmed ID

Honghong Zou, Baoqin Zhou, Gaosi Xu


Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides improvements in glycemic control, they presented excellent performances in direct renoprotective effects and the cardiovascular (CV) safety by decreasing albuminuria and the independent CV risk factors such as body weight and blood pressure, etc. Simultaneous use of SGLT-2 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone. The available population and animal based studies have described SGLT2 inhibitors plus RAAS blockers. The present review was to systematically review the potential renal benefits of SGLT2 inhibitors combined with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and especially the angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.

Twitter Demographics

The data shown below were collected from the profiles of 26 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 104 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 14%
Researcher 11 11%
Student > Ph. D. Student 10 10%
Student > Bachelor 10 10%
Student > Postgraduate 8 8%
Other 20 19%
Unknown 30 29%
Readers by discipline Count As %
Medicine and Dentistry 43 41%
Pharmacology, Toxicology and Pharmaceutical Science 11 11%
Biochemistry, Genetics and Molecular Biology 5 5%
Agricultural and Biological Sciences 5 5%
Computer Science 1 <1%
Other 4 4%
Unknown 35 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2018.
All research outputs
of 13,588,841 outputs
Outputs from Cardiovascular Diabetology
of 794 outputs
Outputs of similar age
of 263,778 outputs
Outputs of similar age from Cardiovascular Diabetology
of 1 outputs
Altmetric has tracked 13,588,841 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 794 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,778 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them